Increased type I collagen synthesis in victims of sudden cardiac death due to idiopathic myocardial fibrosis

References

• Hookana E, Junttila MJ, Puurunen VP, Tikkanen JT, Kaikkonen KS, Kortelainen ML, et al. Causes of nonischemic sudden cardiac death in the current era. Heart Rhythm. 2011;8:1570–5.
   PubMed Web of Science ®Google Scholar
• Weber KT, Janicki JS, Shroff SG, Pick R, Chen RM, Bashey RI. Collagen remodeling of the pressure-overloaded, hypertrophied nonhuman primate myocardium. Circ Res. 1988;62:757–65.
   PubMed Web of Science ®Google Scholar
• Medugorac I, Jacob R. Characterisation of left ventricular collagen in the rat. Cardiovasc Res. 1983;17:15–21.
   PubMed Web of Science ®Google Scholar
• Eghbali M, Weber KT. Collagen and the myocardium: fibrillar structure, biosynthesis and degradation in relation to hypertrophy and its regression. Mol Cell Biochem. 1990;96:1–14.
   PubMed Web of Science ®Google Scholar
• Risteli J, Risteli L. Analysing connective tissue metabolites in human serum. Biochemical, physiological and methodological aspects. J Hepatol. 1995;22:77–81.
   PubMed Web of Science ®Google Scholar
• Bode M, Soini Y, Melkko J, Satta J, Risteli L, Risteli J. Increased amounts of type III pN-collagen in human abdominal aortic aneurysms: evidence for impaired type III collagen fibrillogenesis. J Vasc Surg. 2000;32:1201–7.
   PubMed Web of Science ®Google Scholar
• Biolo A, Rohde LE, Goldraich LA, Mascarenhas M, Palombini DV, Clausell N. Serum procollagen type III is associated with elevated right-sided filling pressures in stable outpatients with congestive heart failure. Biomarkers. 2009;14:438–42.
   PubMed Web of Science ®Google Scholar
• González A, López B, Querejeta R, Zubillaga E, Echeverría T, Díez J. Filling pressures and collagen metabolism in hypertensive patients with heart failure and normal ejection fraction. Hypertension. 2010; 55:1418–24.
   PubMed Web of Science ®Google Scholar
• Alla F, Kearney-Schwartz A, Radauceanu A, Das Dores S, Dousset B, Zannad F. Early changes in serum markers of cardiac extra-cellular matrix turnover in patients with uncomplicated hypertension and type II diabetes. Eur J Heart Fail. 2006;8:147–53.
   PubMed Web of Science ®Google Scholar
• Martos R, Baugh J, Ledwidge M, O’Loughlin C, Conlon C, Patle A, et al. Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction. Circulation. 2007;115: 888–95.
   PubMed Web of Science ®Google Scholar
• Klappacher G, Franzen P, Haab D, Mehrabi M, Binder M, Plesch K, et al. Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis. Am J Cardiol. 1995;75:913–18.
   PubMed Web of Science ®Google Scholar
• Barasch E, Gottdiener JS, Aurigemma G, Kitzman DW, Han J, Kop WJ, et al. Association between elevated fibrosis markers and heart failure in the elderly: the cardiovascular health study. Circ Heart Fail. 2009;2:303–10.
   PubMed Web of Science ®Google Scholar
• Kaikkonen KS, Kortelainen ML, Linna E, Huikuri HV. Family history and the risk of sudden cardiac death as a manifestation of an acute coronary event. Circulation. 2006;114:1462–7.
   PubMed Web of Science ®Google Scholar
• Lahti RA. From findings to statistics: an assessment of Finnish medical cause-of-death information in relation to underlying-cause coding. Helsinki, Finland: Helsinki University Printing House; 2005.
   Google Scholar
• Hookana E, Junttila MJ, Särkioja T, Sormunen R, Niemelä M, Raatikainen MJ, et al. Cardiac arrest and left ventricular fibrosis in a Finnish family with the lamin A/C mutation. J Cardiovasc Electrophysiol. 2008;19:743–7.
   PubMed Web of Science ®Google Scholar
• Kawara T, Derksen R, de Groot JR, Coronel R, Tasseron S, Linnenbank AC, et al. Activation delay after premature stimulation in chronically diseased human myocardium relates to the architecture of interstitial fibrosis. Circulation. 2001;104:3069–75.
   PubMed Web of Science ®Google Scholar
• Lecomte D, Fornes P, Fouret P, Nicolas G. Isolated myocardial fibrosis as a cause of sudden cardiac death and its possible relation to myocarditis. J Forensic Sci. 1993;38:617–21.
   PubMed Web of Science ®Google Scholar
• Zachariah JP, Colan SD, Lang P, Triedman JK, Alexander ME, Walsh EP, et al. Circulating matrix metalloproteinases in adolescents with hypertrophic cardiomyopathy and ventricular arrhythmia. Circ Heart Fail. 2012;5:462–6.
   PubMed Web of Science ®Google Scholar
• Sundström J, Evans JC, Benjamin EJ, Levy D, Larson MG, Sawyer DB, et al. Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures: the Framingham Heart Study. Circulation. 2004;109:2850–6.
   PubMed Web of Science ®Google Scholar
• Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Hafner G, et al.; for the AtheroGene Investigators. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation. 2003;107:1579–85.
   PubMed Web of Science ®Google Scholar
• Timms PM, Mannan N, Hitman GA, Noonan K, Mills PG, Syndercombe-Court D, et al. Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: mechanisms for inflammatory damage in chronic disorders?QJM. 2002;95:787–96.
   PubMed Web of Science ®Google Scholar
• Sundström J, Evans JC, Benjamin EJ, Levy D, Larson MG, Sawyer DB, et al. Relations of plasma total TIMP-1 levels to cardiovascular risk factors and echocardiographic measures: the Framingham heart study. Eur Heart J. 2004;25:1509–16.
   PubMed Web of Science ®Google Scholar
• Timms PM, Wright A, Maxwell P, Campbell S, Dawnay AB, Srikanthan V. Plasma tissue inhibitor of metalloproteinase-1 levels are elevated in essential hypertension and related to left ventricular hypertrophy. Am J Hypertens. 2002;15:269–72.
   PubMed Web of Science ®Google Scholar
• Laviades C, Varo N, Fernández J, Mayor G, Gil MJ, Monreal I, et al. Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation. 1998;98:535–40.
   PubMed Web of Science ®Google Scholar
• Ho CY, López B, Coelho-Filho OR, Lakdawala NK, Cirino AL, Jarolim P, et al. Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. N Engl J Med. 2010;363:552–63.
   PubMed Web of Science ®Google Scholar
• Shim CY, Ha JW, Choi EY, Lee HJ, Moon SH, Kim JM, et al. Relationship between serum biochemical markers of myocardial fibrosis and diastolic function at rest and with exercise in hypertrophic cardiomyopathy. Korean Circ J. 2009;39:519–24.
   PubMedGoogle Scholar
• Polyakova V, Loeffler I, Hein S, Miyagawa S, Piotrowska I, Dammer S, et al. Fibrosis in endstage human heart failure: severe changes in collagen metabolism and MMP/TIMP profiles. Int J Cardiol. 2011;151: 18–33.
   PubMed Web of Science ®Google Scholar